Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc. (NASDAQ: GALT) generates frequent news as a clinical-stage biopharmaceutical company developing galectin-targeted therapies for chronic liver disease and cancer. Most company updates focus on belapectin, its carbohydrate-based galectin-3 inhibitor, and the lead program in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis and portal hypertension.
On this page, readers can follow news about clinical data from the NAVIGATE trial and related analyses, including outcomes on liver stiffness by FibroScan, Enhanced Liver Fibrosis (ELF) scores, and serum biomarkers such as PRO-C3, YKL-40, and PRO-C4. Galectin Therapeutics often reports how these measures relate to the incidence of new esophageal varices and portal hypertension risk categories in patients with compensated MASH cirrhosis.
News items also cover regulatory interactions with the U.S. Food and Drug Administration, such as Type C meeting requests, written feedback on trial design, and plans for potential pivotal Phase 3 development of belapectin. Investors can find announcements about Fast Track designation, presentation of NAVIGATE data at major liver disease meetings like AASLD and EASL, and participation in investor conferences and virtual key opinion leader events.
In addition, Galectin Therapeutics issues press releases on quarterly financial results, new or extended lines of credit and convertible notes, and corporate governance matters. These updates provide context on the company’s capital resources, development priorities, and timing of planned activities. For anyone tracking GALT, this news feed offers a centralized view of clinical milestones, regulatory developments, financing arrangements, and strategic communications related to belapectin and the company’s broader galectin-targeted pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.